Risk factors and outcome of COVID-19 in patients with hematological malignancies
ConclusionsIn most patients with hematological malignancies COVID-19 mortality was directly driven by older age, disease status, performance status, as well as by immune (neutropenia) parameters and level of inflammation (high CRP). Use of azithromycin and low dose corticosteroids may be of value in very severe COVID-19.
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research
More News: Azithromycin | Cancer | Cancer & Oncology | Corticosteroid Therapy | COVID-19 | Hematology | Laboratory Medicine | Pediatrics | SARS | Spain Health | Stem Cell Therapy | Stem Cells | Study | Transplants | Zithromax